Oestrogen patch may cut Alzheimer's risk in some women

Image
IANS New York
Last Updated : Jul 13 2016 | 3:43 PM IST

Administering the primary female sex hormone oestrogen via a skin patch shortly after menopause may reduce Alzheimer's risk in women, suggests new research.

The study, published in the Journal of Alzheimer's Disease, found that newly postmenopausal women who received oestrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer's disease.

"This study showed, for the first time, that the brain amyloid deposition -- a hallmark of Alzheimer's disease -- is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy," said lead author Kejal Kantarci from Mayo Clinic in the US.

In the study, women with APOE e4 -- one form of the most common gene associated with late-onset Alzheimer's disease -- had lower levels of amyloid deposits.

"Women with APOE e4, who have a greater genetic risk for Alzheimer's disease, particularly benefited from this therapy," Kantarci noted.

Menopause is defined as occurring 12 months after a woman's last menstrual period and marks the end of menstrual cycles.

The researchers used data from a larger study - Kronos Early Estrogen Prevention Study.

The study aimed to determine the effects of menopausal hormone therapy shortly after menopause, during the critical window of rapid oestrogen depletion -- five to 36 months past menopause.

Researchers investigated the brain amyloid deposition in 68 women aged 42 to 59 who participated in the Kronos study.

The researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.

Of the 68 women, 21 received oestrogen via a skin patch, 17 received estrogen orally and 30 received a placebo.

Amyloid deposition was lower in women who received the patch, compared to the placebo, and the effect was most apparent in women with the APOE e4 genotype.

The oral treatment was not associated with lower amyloid deposition.

--IANS

gb/vt

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 13 2016 | 3:26 PM IST

Next Story